N/A N=91 Microvascular Blood Flow in Sickle Cell Anemia
Sickle Cell Disease · Sickle Cell Anemia
Primary: Microvascular Blood Flow Rate Change — 1.09; 0.86 Ratio of change
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=48 Test of the Safety, Effectiveness, & Acceptability of An Improvised Dressing for Sickle Cell Leg Ulcers in the Tropics
Sickle Cell Leg Ulcer
Primary: Number of Participants Who Experienced a Wound Complication (A Measure of Dressing Safety) — 4; 0; 0 Participants
Phase 3 N=251 Low Dose Aspirin for Venous Leg Ulcers
Venous Leg Ulcer
Primary: Time to Complete Healing of Reference Ulcer — 77; 69 days — p=0.246
Phase 2 N=23 Phase II Randomized Trial:Arginine Butyrate Plus Standard Local Therapy in Patients With Refractory Sickle Cell Ulcers
Skin Ulcers · Sickle Cell Anemia
Primary: Healing Defined as a Decrease in Ulcer Area by at Least 25% of the Initial Area — 24; 78 percentage of healed ulcers — p=0.05
Phase 2 N=29 Treatment of Sickle Cell Patients Hospitalized in Pain Crisis With Prophylactic Dose Low-molecular-weight Heparin (LMWH) Versus Placebo
Sickle Cell Disease · Vaso-occlusive Crisis
Primary: Change in D-dimer — 478.8; 260.1 ng/mL
Phase 2 N=29 The Effect of the Cosmetic Cream NMBM on Leg Ulcers - a Pilot Study
Ulcer · Venous Ulcer · Skin Ulcer
Primary: Logarithm of Percentage of Baseline Ulcer Size — 3.6043; 3.5030 Mean of log (percentage of baseline area — p=0.652
Phase 2 N=109 Effectiveness of Arginine as a Treatment for Sickle Cell Anemia
Anemia, Sickle Cell
Primary: Gardos Channel Activity — -0.0342; 0.0043; 0.1076 mmol/10^13 cells x min — p=0.080
Phase 2 N=140 Cooling Leg and Foot Ulcer Skin Post Healing to Prevent Ulcer Recurrence
Venous Hypertension Ulcers · Venous Stasis Ulcer · Venous Ulcer
Primary: Number of Participants With Ulcer Recurrence — 6; 3; 11; 5 participants — p=0.091
N/A N=144 Self-Management to Prevent Ulcers in Veterans With SCI (Spinal Cord Injury)
Pressure Ulcers · Spinal Cord Injuries
Primary: Percent of Possible Self-Reported Skin Care Behaviors — 73.8; 74.1; 83.5; 79.5 % of Possible Self-Reported Behaviors
Phase 2 N=121 Dose-response Relationship Study of S42909 on Leg Ulcer Healing
Venous Leg Ulcer
Primary: Relative Reduction of Reference Ulcer Area After 4 Weeks of Treatment on Top of Standard of Care Compared With Baseline Reference Ulcer Area (W000) Assessed During Study…
Phase 2 N=46 Fixed Dose Flavonoid Isoquercetin on Thrombo-Inflammatory Biomarkers in Subjects With Stable Sickle Cell Disease
Sickle Cell Disease
Primary: Mean Change in the Plasma Soluble P-selectin Level — 0.74; 0.10 ng/ml — p=0.64
Phase 2 N=37 Antioxidant Therapy to Reduce Inflammation in Sickle Cell Disease
Anemia, Sickle Cell
Primary: C-Reactive Protein — 11.4; 6.8 mg/l
N/A N=25 Measurement of Cerebral Blood Flow Using Transcranial Doppler Ultrasound in Children With Sickle Cell Disease
Sickle Cell Disease
Primary: Measurement of Time Average Mean of the Maximum (TAMM) in cm/Sec in Cerebral Arteries Using 2 Different Ultrasound Machines. — 120; 120 cm/sec
Phase 2 N=228 Dose Finding Study of HP802-247 in Venous Leg Ulcers
Venous Leg Ulcer · Venous Stasis Ulcers
Primary: The Average Percent (%) Change From Baseline in the Target Wound Area in Each Treatment Group Over the Twelve-week Double-blind Treatment Period. — -77.11; -70.15…
Phase 3 N=155 Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers >12 cm2 to ≤ 36 cm2
Venous Leg Ulcers
Primary: Wound Closure — 17; 23 participants
Phase 3 N=68 Efficacy of the Combination of Isosorbide Dinitrate Spray and Chitosan in Diabetic Foot Ulcers
Diabetic Foot Ulcers
Primary: Biopsies — 2.46; 2.64; 2.56; 2.07 UI/dL
N/A N=28 Predictive of Biomarkers of Healing in Chronic Venous Ulceration of the Lower Limb
Varicose Ulcer
Primary: Identification of Biomarkers Predictive of Ulcer Healing. — 9 Number of biomarkers
N/A N=81 Effects of Non Contact Low Frequency Ultrasound in Healing Venous Leg Ulcers
Venous Insufficiency · Venous Reflux · Lower Extremity Ulcer
Primary: Wound Area Mean Percent Reduction — 45.8; 61.6 percentage of mean area reduction — p=<0.024
N/A N=8 ULCERS - Electrical Stimulation in Diabetic Foot Ulceration
Diabetes
Primary: Number of Day Until 50% Healing of Leg Ulcer — 55; 30 Days
N/A N=83 Leg Ulcers Standards of Care Enhancement
Venous Leg Ulcer · Mixed Leg Ulcer
Primary: Percentage Change of the Wound Area — 42.41; 60.75; 25.18; 72.16 percentage of change
Phase 2 N=80 Herbal Preparation Used as Adjuvant Therapy on Diabetic Ulcers
Diabetic Foot Ulcer · Amputation
Primary: Number of Participants With Limb Salvage — 37; 31 Participants
N/A N=47 MIST Ultrasound Therapy Compared to United Kingdom Standard Care for the Treatment of Non-healing Venous Leg Ulcers
Varicose Ulcer
Primary: Percentage Change in Wound Area — -39.2; -46.6 percentage change in wound area — p=0.565
N/A N=112 Sickle Cell Anemia WE CARE
Sickle Cell Disease
Primary: Number of Emergency Department (ED)/Acute Care Visits — 0; 1 number of visits
N/A N=483 Comparison of Patient Centered Outcomes for People With Sickle Cell Disease in the Acute Care Setting
Sickle Cell Disease
Primary: Time (Minutes) From Arrival to Center to Time First Dose of Parenteral Pain Medication Administered — 125.3; 61.8 minutes
Phase 1 N=4 A Phase 1 Study of Continuous Intravenous L-citrulline During Sickle Cell Pain Crisis or Acute Chest Syndrome
Sickle Cell Disease
Primary: Number of Participants With Adverse Events — 4 Participants
Phase 2 N=175 Preventing Diabetic Foot Ulcers Through Cleaner Feet
Diabetic Foot Ulcer
Primary: Time to New Foot Complication Among All Randomized Participants — 12; 14 Participants
N/A N=67 Using Patient-Centered Guidelines in a Technology Platform to Improve Health Care in Adults With Sickle Cell Disease
Sickle Cell Disease
Primary: SCD-specific Knowledge — 32.0; 32.0; 33.5; 33 score on a scale
N/A N=12 A Non-significant Risk Clinical Study of Therapeutic Ultrasound for Patients With Diabetic Foot Ulcers.
Diabetic Foot Ulcer · Peripheral Arterial Disease · Wound; Foot
Primary: Transcutaneous Oxygen Pressure (TcPO2) — 50.96 mmHg
Phase 3 N=447 Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers
Venous Leg Ulcers
Primary: Compare the Treatment Groups for the Proportion of Subjects With Complete Wound Closure Over the 12-Week Treatment Period From Baseline — 129; 126; 82; 84 participants…
N/A N=120 Decision Aid for Therapeutic Options In Sickle Cell Disease
Sickle Cell Disease · Sickle Cell Anemia · Hemoglobin SS
Primary: Acceptability of Decision Aid Education Assessed by the Acceptability Survey — 3; 3; 3; 3 units on a scale